{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:22:09Z","timestamp":1786926129874,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.cgh.2017.01.026","type":"journal-article","created":{"date-parts":[[2017,2,4]],"date-time":"2017-02-04T03:01:15Z","timestamp":1486177275000},"page":"1021-1029.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2\u00a0and 3 Studies of Patients With Irritable Bowel Syndrome With\u00a0Diarrhea"],"prefix":"10.1016","volume":"15","author":[{"given":"Reginald V.","family":"Fant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack E.","family":"Henningfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8497-3349","authenticated-orcid":false,"given":"Brooks D.","family":"Cash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard S.","family":"Dove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Covington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2017.01.026_bib1","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/j.gastro.2012.08.002","article-title":"Burden of gastrointestinal disease in the United States: 2012 update","volume":"143","author":"Peery","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.01.026_bib2","first-page":"299","article-title":"The burden of illness of irritable bowel syndrome: current challenges and hope for the future","volume":"10","author":"Hulisz","year":"2004","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.cgh.2017.01.026_bib3","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.clinthera.2006.10.010","article-title":"Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study","volume":"28","author":"Par\u00e9","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.cgh.2017.01.026_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2017.01.026_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00535-013-0753-x","article-title":"Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives","volume":"49","author":"Sobczak","year":"2014","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cgh.2017.01.026_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-3-540-33823-9_2","article-title":"Opioids","volume":"177","author":"Z\u00f6llner","year":"2007","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.cgh.2017.01.026_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0163-7258(95)02053-5","article-title":"Insights into opioid action in the intestinal tract","volume":"69","author":"De Luca","year":"1996","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.01.026_bib8","first-page":"470","article-title":"New insights into the pathogenesis of intestinal dysfunction: secretory diarrhea and cystic fibrosis","volume":"6","author":"Barrett","year":"2000","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.01.026_bib9","doi-asserted-by":"crossref","first-page":"E118","DOI":"10.1208\/aapsj080114","article-title":"Opioid ligands with mixed mu\/delta opioid receptor interactions: an emerging approach to novel analgesics","volume":"8","author":"Ananthan","year":"2006","journal-title":"AAPS J"},{"key":"10.1016\/j.cgh.2017.01.026_bib10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/bja\/aep129","article-title":"Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile","volume":"103","author":"Dietis","year":"2009","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.cgh.2017.01.026_bib11","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1476-5381.2012.02068.x","article-title":"Modulation of gastrointestinal function by MuDelta, a mixed \u03bc opioid receptor agonist\/ \u03bc opioid receptor antagonist","volume":"167","author":"Wade","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cgh.2017.01.026_bib12","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1523\/JNEUROSCI.20-15-05874.2000","article-title":"Kappa -opioid receptor agonists modulate visceral nociception at a novel, peripheral site of action","volume":"20","author":"Joshi","year":"2000","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.cgh.2017.01.026_bib13","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1073\/pnas.90.12.5391","article-title":"A\u00a0brief history of opiates, opioid peptides, and opioid receptors","volume":"90","author":"Brownstein","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cgh.2017.01.026_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1151\/spp021113","article-title":"The neurobiology of opioid dependence: implications for treatment","volume":"1","author":"Kosten","year":"2002","journal-title":"Sci Pract Perspect"},{"key":"10.1016\/j.cgh.2017.01.026_bib15","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/clpt.1980.239","article-title":"Abuse potential of loperamide","volume":"28","author":"Jaffe","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.01.026_bib16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/clpt.1980.93","article-title":"Dependence liability of two antidiarrheals, nufenoxole and loperamide","volume":"27","author":"Korey","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.01.026_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-209705","article-title":"Loperamide dependence and abuse","author":"MacDonald","year":"2015","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.cgh.2017.01.026_bib18","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jcph.442","article-title":"Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline","volume":"55","author":"Davenport","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cgh.2017.01.026_bib19","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.01.026_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/j.gastro.2013.04.006","article-title":"Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study","volume":"145","author":"Dove","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.01.026_bib21","unstructured":"US Food and Drug Administration. Guidance for industry: assessment of abuse potential of drugs [Web site]. Available at: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm198650.pdf. Accessed December 8,\u00a02015."},{"key":"10.1016\/j.cgh.2017.01.026_bib22","unstructured":"Pharmaceutical Research and Manufacturers of America, US Food and Drug Administration. PhRMA-FDA dialogue session: abuse potential assessments. Bethesda, MD, February 20, 2008."},{"key":"10.1016\/j.cgh.2017.01.026_bib23","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/j.drugalcdep.2014.02.367","article-title":"A\u00a0new standardised MedDRA query to address drug abuse-related safety signals","volume":"140","author":"Love","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.cgh.2017.01.026_bib24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/00952998709001515","article-title":"Two new rating scales for opiate withdrawal","volume":"13","author":"Handelsman","year":"1987","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.cgh.2017.01.026_bib25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0376-8716(03)00015-2","article-title":"Buprenorphine dosing regime for inpatient heroin withdrawal: a symptom-triggered dose titration study","volume":"70","author":"Lintzeris","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.cgh.2017.01.026_bib26","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/1740774513492917","article-title":"Concealment and fabrication by experienced research subjects","volume":"10","author":"Devine","year":"2013","journal-title":"Clin Trials"},{"key":"10.1016\/j.cgh.2017.01.026_bib27","first-page":"S521","article-title":"Lack of subjective abuse-related effects of intranasal eluxadoline: a novel mu-delta opiate modulator for oral use in IBS-d","volume":"38","author":"Levy-Cooperman","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.cgh.2017.01.026_bib28","unstructured":"Levy-Cooperman N, McIntyre G, Bonifacio L, et\u00a0al. Lack of subjective abuse-related effects of oral eluxadoline: a novel mu-delta opiate modulator for oral use in IBS-D. Poster presented at the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, San Diego, CA, March 8\u201312,\u00a02016."}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356517301349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356517301349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:22:24Z","timestamp":1761542544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356517301349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1542356517301349"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2017.01.026","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727289172.793556887","asserted-by":"object"}]},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2\u00a0and 3 Studies of Patients With Irritable Bowel Syndrome With\u00a0Diarrhea","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2017.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}